BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $0.07, $0.18 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $501.7 million versus the consensus estimate of $448.79 million.

GUIDANCE:

BioMarin Pharma sees FY 2021 revenue of $1.75-1.85 billion, versus the consensus of $1.82 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.